자동 핵산 추출 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 기술별, 용도별, 최종 용도별, 지역별, 부문별 예측(2025-2033년)

Automated Nucleic Acid Extraction Market Summary

The global automated nucleic acid extraction market size was valued at USD 3.22 billion in 2024 and is expected to reach USD 8.77 billion by 2033, registering a CAGR of 11.89% from 2025 to 2033. Continuous advancements in extraction technologies, combined with the growing applications of genomics in precision medicine, infectious disease testing, and biotechnology research, are further driving market expansion.

Technological innovation enabling new sample types and challenging technologies

Technological developments are stimulating the robust adoption of automated nucleic acid extraction systems by making it easier to process complex sample types, such as those with shallow volumes, clinical samples, FFPE tissues, and circulating cell-free nucleic acids. These developments will provide increased sensitivity, reproducibility, and throughput, while yielding high-quality DNA/RNA that is essential for diagnostics, precision medicine, and research.

Moreover, advanced automated solutions are now finely integrated into downstream technologies such as high-throughput PCR, NGS library preparation, and digital PCR, to lessen manual handling and improve turnaround times. Overall, as healthcare and research environments move towards automation, high-volume genomic testing, and precision oncology, automated nucleic acid extraction is increasingly essential to contemporary molecular technologies.

Global Automated Nucleic Acid Extraction Market Report Segmentation

This report forecasts revenue growth at the global, regional and country levels and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global automated nucleic acid extraction market report on the basis of product, technology, application, end use, and region:

• Product Outlook (Revenue, USD Million, 2021 - 2033)
• Instruments
• Reagents & Consumables
• Technology Outlook (Revenue, USD Million, 2021 - 2033)
• Magnetic Bead-based
• Column-based
• Others
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• DNA Extraction
  • Genomic DNA Extraction
  • Plasmid DNA Extraction
  • Others
• RNA Extraction
  • mRNA Extraction
  • miRNA Extraction
  • Total RNA Extraction
  • Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations
• Hospitals and Diagnostic Centers
• Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
  • 1.2.1. Information analysis
  • 1.2.2. Market formulation & data visualization
  • 1.2.3. Data validation & publishing
• 1.3. Information Procurement
  • 1.3.1. Primary Others
• 1.4. Information or Data Analysis
• 1.5. Market Formulation & Validation
• 1.6. Market Model
• 1.7. Objectives
  • 1.7.1. Objective 1
  • 1.7.2. Objective 2

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Drivers
  • 3.3.1. Rising Adoption of Genomics and Precision Medicine Driving Automation in Nucleic Acid Extraction
  • 3.3.2. Technological innovation enabling new sample types and challenging technologies
• 3.4. Market Restraint Analysis
  • 3.4.1. Operational and Maintenance Complexity
• 3.5. Business Environment Analysis
  • 3.5.1. PESTEL Analysis
  • 3.5.2. Porter's Five Forces Analysis

Chapter 4. Product Business Analysis

• 4.1. Global Automated Nucleic Acid Extraction Market: Service Type Movement Analysis
• 4.2. Instruments
  • 4.2.1. Instruments, 2021 - 2033 (USD Million)
• 4.3. Reagents & Consumables
  • 4.3.1. Reagents & Consumables, 2021 - 2033 (USD Million)

Chapter 5. Technology Business Analysis

• 5.1. Global Automated Nucleic Acid Extraction market: Technology Movement Analysis
• 5.2. Magnetic Bead-based
  • 5.2.1. Magnetic Bead-based, 2021 - 2033 (USD Million)
• 5.3. Column-based
  • 5.3.1. Column-based, 2021 - 2033 (USD Million)
• 5.4. Others
  • 5.4.1. Others, 2021 - 2033 (USD Million)

Chapter 6. Application Business Analysis

• 6.1. Global Automated Nucleic Acid Extraction market: Application Movement Analysis
• 6.2. DNA Extraction
  • 6.2.1. DNA Extraction, 2021 - 2033 (USD Million)
    • 6.2.1.1. Genomic DNA Extraction
      • 6.2.1.1.1. Genomic DNA Extraction, 2021 - 2033 (USD Million)
    • 6.2.1.2. Plasmid DNA Extraction
      • 6.2.1.2.1. Plasmid DNA Extraction, 2021 - 2033 (USD Million)
    • 6.2.1.3. Others
      • 6.2.1.3.1. Others, 2021 - 2033 (USD Million)
• 6.3. RNA Extraction
  • 6.3.1. RNA Extraction ,2021 - 2033 (USD Million)
    • 6.3.1.1. mRNA Extraction
      • 6.3.1.1.1. mRNA Extraction, 2021 - 2033 (USD Million)
    • 6.3.1.2. miRNA Extraction
      • 6.3.1.2.1. miRNA Extraction, 2021 - 2033 (USD Million)
    • 6.3.1.3. Total RNA Extraction
      • 6.3.1.3.1. Total RNA Extraction, 2021 - 2033 (USD Million)
    • 6.3.1.4. Others
      • 6.3.1.4.1. Others, 2021 - 2033 (USD Million)

Chapter 7. End-use Business Analysis

• 7.1. Global Automated Nucleic Acid Extraction Market: End-use Movement Analysis
• 7.2. Universities & Other Research Entities
• 7.3. Academic & Research Institutes
  • 7.3.1. Academic & Research Institutes,2021 - 2033 (USD Million)
• 7.4. Pharmaceutical & Biotechnology Companies
  • 7.4.1. Pharmaceutical & Biotechnology Companies,2021 - 2033 (USD Million)
• 7.5. Contract Research Organizations
  • 7.5.1. Contract Research Organizations,2021 - 2033 (USD Million)
• 7.6. Hospitals and Diagnostic Centers
  • 7.6.1. Hospitals and Diagnostic Centers,2021 - 2033 (USD Million)
• 7.7. Others
  • 7.7.1. Others,2021 - 2033 (USD Million)

Chapter 8. Regional Business Analysis

• 8.1. Global Automated Nucleic Acid Extraction Market Share by Region, 2024 & 2033
• 8.2. North America
  • 8.2.1. North America Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. Key Country Dynamics
    • 8.2.2.2. Competitive Scenario
    • 8.2.2.3. Regulatory Framework
    • 8.2.2.4. Target Disease Prevalence
    • 8.2.2.5. U.S. Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Key Country Dynamics
    • 8.2.3.2. Competitive Scenario
    • 8.2.3.3. Regulatory Framework
    • 8.2.3.4. Target Disease Prevalence
    • 8.2.3.5. Canada Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Key Country Dynamics
    • 8.2.4.2. Competitive Scenario
    • 8.2.4.3. Regulatory Framework
    • 8.2.4.4. Target Disease Prevalence
    • 8.2.4.5. Mexico Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.3.2. Germany
    • 8.3.2.1. Key Country Dynamics
    • 8.3.2.2. Competitive Scenario
    • 8.3.2.3. Regulatory Framework
    • 8.3.2.4. Target Disease Prevalence
    • 8.3.2.5. Germany Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.3.3. UK
    • 8.3.3.1. Key Country Dynamics
    • 8.3.3.2. Competitive Scenario
    • 8.3.3.3. Regulatory Framework
    • 8.3.3.4. Target Disease Prevalence
    • 8.3.3.5. UK Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. Key Country Dynamics
    • 8.3.4.2. Competitive Scenario
    • 8.3.4.3. Regulatory Framework
    • 8.3.4.4. Target Disease Prevalence
    • 8.3.4.5. France Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Key Country Dynamics
    • 8.3.5.2. Competitive Scenario
    • 8.3.5.3. Regulatory Framework
    • 8.3.5.4. Target Disease Prevalence
    • 8.3.5.5. Italy Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Key Country Dynamics
    • 8.3.6.2. Competitive Scenario
    • 8.3.6.3. Regulatory Framework
    • 8.3.6.4. Target Disease Prevalence
    • 8.3.6.5. Spain Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Key Country Dynamics
    • 8.3.7.2. Competitive Scenario
    • 8.3.7.3. Regulatory Framework
    • 8.3.7.4. Target Disease Prevalence
    • 8.3.7.5. Denmark Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.3.8. Sweden
    • 8.3.8.1. Key Country Dynamics
    • 8.3.8.2. Competitive Scenario
    • 8.3.8.3. Regulatory Framework
    • 8.3.8.4. Target Disease Prevalence
    • 8.3.8.5. Sweden Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.3.9. Norway
    • 8.3.9.1. Key Country Dynamics
    • 8.3.9.2. Competitive Scenario
    • 8.3.9.3. Regulatory Framework
    • 8.3.9.4. Target Disease Prevalence
    • 8.3.9.5. Norway Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.4.2. Japan
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. Target Disease Prevalence
    • 8.4.2.5. Japan Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.4.3. China
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Target Disease Prevalence
    • 8.4.3.5. China Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Target Disease Prevalence
    • 8.4.4.5. India Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. Key Country Dynamics
    • 8.4.5.2. Competitive Scenario
    • 8.4.5.3. Regulatory Framework
    • 8.4.5.4. Target Disease Prevalence
    • 8.4.5.5. South Korea Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Key Country Dynamics
    • 8.4.6.2. Competitive Scenario
    • 8.4.6.3. Regulatory Framework
    • 8.4.6.4. Target Disease Prevalence
    • 8.4.6.5. Australia Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Key Country Dynamics
    • 8.4.7.2. Competitive Scenario
    • 8.4.7.3. Regulatory Framework
    • 8.4.7.4. Target Disease Prevalence
    • 8.4.7.5. Thailand Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. Target Disease Prevalence
    • 8.5.2.5. Brazil Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Target Disease Prevalence
    • 8.5.3.5. Argentina Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
• 8.6. MEA
  • 8.6.1. MEA Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.6.2. South Africa
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Target Disease Prevalence
    • 8.6.2.5. South Africa Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.6.3. Saudi Arabia
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. Target Disease Prevalence
    • 8.6.3.5. Saudi Arabia Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.6.4. UAE
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. Target Disease Prevalence
    • 8.6.4.5. UAE Automated nucleic acid extraction market, 2021 - 2033 (USD Million)
  • 8.6.5. Kuwait
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Target Disease Prevalence
    • 8.6.5.5. Kuwait Automated nucleic acid extraction market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Strategy Mapping
• 9.3. Company Market Position Analysis, 2024
• 9.4. Company Profiles/Listing
  • 9.4.1. Thermo Fisher Scientific, Inc.
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Product Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. QIAGEN
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Product Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Merck KGaA
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Product Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. F. Hoffmann-La Roche AG
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Product Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Agilent Technologies
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Product Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. Revvity, Inc.
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Product Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. Promega Corporation
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Product Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Bio-Rad Laboratories
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Product Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Takara Bio
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Product Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Zymo Research Corporation
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Product Benchmarking
    • 9.4.10.4. Strategic Initiatives